Vol 16, No 3 (2022)
Case report
Published online: 2022-07-18

open access

Page views 3964
Article views/downloads 339
Get Citation

Connect on Social Media

Connect on Social Media

Impact of persistent coronavirus infection on the treatment of an immunocompromised oncological patient

Martyna Gołębiewska1, Olga Piątek2, Krzysztof Kuziemski2, Tomasz Stefaniak34
Palliat Med Pract 2022;16(3):183-186.

Abstract

The emergence of the coronavirus pandemic in 2020 has challenged many aspects of the management of clinical care. It has negatively impacted the already overwhelmed healthcare system in Poland, leading to further limitation of access to specialist care, delay of treatment and even failure to initiate it. Patients with severe, rapidly progressing diseases such as cancer, are among those most adversely affected. Immunocompromised patients are prone to persistent COVID-19 infection and re-test positively even when asymptomatic. In this case report, the authors present an immunocompromised patient with follicular lymphoma and active tuberculosis, who re-tested positive for SARS-CoV-2 in real-time polymerase chain reaction and rapid antigen tests twenty-two times over seventeen weeks of hospitalisation in the isolation ward in University Clinical Centre in Gdansk, Poland. The management of her oncological treatment was significantly disturbed by prolonged isolation and organisational issues arising from the coronavirus pandemic.

Article available in PDF format

View PDF Download PDF file

References

  1. Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. The Lancet Oncology. 2020; 21(3): 335–337.
  2. Poland COVID – Coronavirus Statistics – Worldometer [Internet]. Worldometers.info. 2021. https://www.worldometers.info/coronavirus/country/poland/ (1 Feb 2022).
  3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. The Lancet. 2020; 395(10223): 507–513.
  4. Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: A perspective. J Glob Health. 2020; 10(1): 010367.
  5. Moran Ed, Cook T, Goodman AL, et al. Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials. Lancet Infect Dis. 2021; 21(10): 1345–1347.
  6. Evans RA, McAuley H, Harrison E, et al. Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. Lancet Respir Med. 2021; 9(11): 1275–1287.